A 30-year conservation effort has helped the critically endangered Galápagos snapdragon (Galvezia leucantha subsp. leucantha) recover from just six individuals to a small, carefully tended wild population. Following tireless conservation efforts and the planting of 94 nursery-propagated plants that were reintroduced to Playa Tortuga Negra and Caleta Tagus, the wild adult population has grown from six individuals in 2007 to 28 healthy adults today – 20 at Playa Tortuga Negra and 8 at Tagus Cove. In 2021, the project recorded its first evidence of natural seedling regeneration in the wild — a significant milestone demonstrating that the reintroduced plants were able to reproduce naturally and generate a new generation under wild conditions. Although these first naturally recruited seedlings did not survive a later drought, their emergence represents an important step toward a self-sustaining population and highlights the value of the long-term restoration effort. Their loss also underscores an important remaining challenge. Water scarcity remains one of the biggest ongoing threats to this critically endangered plant.The full study has been published in Nature Conservation, an open-access journal.

One of the major risk factors for Glaucoma is an increase in intraocular pressure. Intraocular pressure fluctuates throughout the day and is known to rise at night, but the detailed molecular mechanisms on why this happens have not been fully understood. Kyushu University researchers found that norepinephrine raises levels of RHOB in the eye’s drainage system called the trabecular meshwork, leading to the eye’s ‘cleaning function’ weakening and increased intraocular pressure.

The U.S. National Science Foundation has renewed the Quantum Leap Challenge Institute for Quantum Sensing for Biophysics and Bioengineering (NSF QuBBE) with a $37.5 million, five-year investment to advance quantum sensing technologies that can reveal biological processes difficult or impossible to observe with conventional tools.

Type 2 diabetes (T2D) develops through the long-term interplay of genetic predisposition, lifestyle, and environmental exposures. Residential greenness is increasingly studied as a measurable environmental exposure that may be related to diabetes risk. However, prospective evidence from Chinese populations remains limited, and whether genetic susceptibility modifies the greenness–T2D association, particularly in terms of absolute risk reduction, has remained unclear.

Metabolic dysfunction-associated steatotic liver disease (MASLD), which affects about 30% of the population worldwide, is driven in part by excessive hepatic de novo lipogenesis (the production of fatty acids within the liver). In mice, the minor intron splicing factors ZRSR1 and ZRSR2 can influence hepatic lipid metabolism by controlling the processing of Insig transcripts. Whether these proteins also regulate metabolism independently of their canonical splicing function has remained unclear.

Chronic kidney disease (CKD) affects millions worldwide, with renal fibrosis representing a final common pathway of chronic renal injury. Defective fatty acid oxidation (FAO) in renal tubular epithelial cells has been shown to promote kidney fibrosis, but whether FAO impairment in kidney vascular endothelial cells contributes to renal pathology has remained unclear.

Perivascular adipose tissue (PVAT), the fat layer surrounding blood vessels, is increasingly recognized as an active regulator of vascular function rather than a passive structural cushion. Yet whether PVAT contains functionally important sympathetic nerves has remained debated, largely because conventional two-dimensional imaging can miss sparse, spatially complex neural structures.

Atherosclerotic cardiovascular disease (ASCVD) remains a leading cause of death worldwide. Elevated low-density lipoprotein cholesterol (LDL-C) is a major modifiable driver of ASCVD, and PCSK9 has become an important therapeutic target because it regulates hepatic LDL receptor recycling and circulating LDL-C levels. Although PCSK9-targeting monoclonal antibodies and siRNA therapies can substantially lower LDL-C, their cost and need for repeated administration have motivated efforts to develop longer-lasting and more accessible approaches.